评估罕见及非编码药物遗传变异功能后果的计算工具
药物反应个体差异部分由已知遗传多态性解释,但仍有大量遗传力缺失。群体测序项目发现数万编码和非编码药物遗传变异功能不明。本文综述各类变异计算预测工具在药物基因组学中的效用,主张开发基于药物基因组学数据训练的算法以提高预测准确性。
要点
- 传统预测方法基于进化保守性,对保守性差的药物基因预测准确性大幅降低
- 需关注错义、同义、剪接及非编码变异的功能评估工具进展
- 倡导基于药物基因组学数据而非致病性数据训练算法以提升预测准确性
核心结论
- 将个体变异特征转化为药物反应预测和可操作建议仍是当代药物基因组学重要前沿。
- 传统基于进化保守性的预测方法对保守性差的药物基因预测准确性大幅降低。
- 倡导开发基于药物基因组学而非致病性数据集训练的算法以提高预测准确性。
研究设计与样本
- 本文为综述,检索范围未在摘要中具体报告。
主要发现
- 群体规模测序项目已发现数万个编码和非编码药物遗传变异,功能效应不明。
- 已知遗传多态性仍不能解释相当大比例的遗传药理学和毒理学变异。
- 综述涵盖错义、同义、剪接和非编码变异的计算预测工具进展。
- 讨论了评估单倍型和结构变异的新兴可能性。
临床怎么用
- 临床解读罕见或非编码药物遗传变异时,应认识传统保守性预测工具的局限性。
- 利用下一代测序数据支持个体化临床决策前,需谨慎评估变异功能预测的可靠性。
局限性
- 摘要未报告具体检索策略、纳入研究数量或预测工具性能比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interindividual differences in drug response are a common concern in both drug development and across layers of care. While genetics clearly influences drug response and toxicity of many drugs, a substantial fraction of the heritable pharmacological and toxicological variability remains unexplained by known genetic polymorphisms. In recent years, population-scale sequencing projects have unveiled tens of thousands of coding and noncoding pharmacogenetic variants with unclear functional effects that might explain at least part of this missing heritability. However, translating these personalized variant signatures into drug response predictions and actionable advice remains challenging and constitutes one of the most important frontiers of contemporary pharmacogenomics. Conventional prediction methods are primarily based on evolutionary conservation, which drastically reduces their predictive accuracy when applied to poorly conserved pharmacogenes. Here, we review the current state-of-the-art of computational variant effect predictors across variant classes and critically discuss their utility for pharmacogenomics. Besides missense variants, we discuss recent progress in the evaluation of synonymous, splice, and noncoding variations. Furthermore, we discuss emerging possibilities to assess haplotypes and structural variations. We advocate for the development of algorithms trained on pharmacogenomic instead of pathogenic data sets to improve the predictive accuracy in order to facilitate the utilization of next-generation sequencing data for personalized clinical decision support and precision pharmacogenomics.
引用
- Zhou Y, Lauschke VM. Computational Tools to Assess the Functional Consequences of Rare and Noncoding Pharmacogenetic Variability. Clin Pharmacol Ther. 2021. PMID: 33998671. doi:10.1002/cpt.2289
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。